|
2024
|
Invention
|
Imidazole-containing inhibitors of alk2 kinase.
Disclosed are compounds of formula I, II, III, a... |
|
|
Invention
|
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibit... |
|
|
Invention
|
Oral dosage forms and oral dosing regimens for treatment of complement mediated diseases. Disclos... |
|
2023
|
Invention
|
Methods of treating hematologic cancers.
The present application relates to treatment of hematol... |
|
|
Invention
|
Fusion protein inhibitors of klk5. Disclosed are polypeptides that are useful for, among other th... |
|
|
Invention
|
Human plasma kallikrein inhibitors. Disclosed are compounds of formula I
as described herein, an... |
|
|
Invention
|
Crystalline salts of a plasma kallikrein inhibitor.
Disclosed are crystalline salts of Compound ... |
|
|
Invention
|
Imidazole-containing inhibitors of alk2 kinase. Disclosed are compounds of formula I, II, III, an... |
|
|
Invention
|
Synthesis of an antiviral azasugar triphosphate.
Provided are methods of making the active 5′-tr... |
|
|
Invention
|
Benzopyrazole compounds and analogues thereof.
Disclosed are compounds of formula I, and pharmac... |
|
2022
|
Invention
|
Bicyclic heteroaromatic inhibitors of klk5.
Disclosed are compounds of formulae (I)-(IV), and ph... |
|
|
Invention
|
Bicyclic heteroaromatic inhibitors of klk5. Disclosed are compounds of formulae (I) - (IV), and p... |
|
2021
|
Invention
|
Dosing regimens for oral alk2 kinase inhibitors.
Disclosed are dosage forms of compounds and pha... |
|
|
Invention
|
Dosing regimens for oral alk2 kinase inhibitors. Disclosed are dosage forms of compounds and phar... |
|
|
Invention
|
Human plasma kallikrein inhibitors. Disclosed are compounds of formula I:
as described herein, a... |
|
|
Invention
|
Human plasma kallikrein inhibitors. Disclosed are compounds of formula I
as described herein... |
|
|
Invention
|
Methods and compositions for inhibition of polymerase.
The present invention is directed to meth... |
|
|
Invention
|
Crystalline salts of a plasma kallikrein inhibitor. Disclosed are crystalline salts of Compound I... |
|
|
Invention
|
Antiviral treatments. The invention provides unit dosage forms, kits, and methods useful for trea... |
|
|
Invention
|
Human plasma kallikrein inhibitors. Disclosed are compounds of formula I, and pharmaceutically ac... |
|
|
P/S
|
Pharmaceutical research services; pharmaceutical drug development services; medical and scientifi... |
|
|
Invention
|
Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections.
Provided are ... |
|
|
Invention
|
Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections. Provided are c... |
|
|
Invention
|
Pyrrolopyrimidine amines as complement inhibitors.
Disclosed are compounds of formula (I), and p... |
|
|
Invention
|
Pyrrolopyrimidine amines as complement inhibitors. Disclosed are compounds of formula (I), and ph... |
|
|
Invention
|
Methods and compositions for treatment of zika virus infection. Disclosed are compounds of formul... |
|
2020
|
Invention
|
Oral complement factor d inhibitors. Disclosed are compounds of formula (I)-(IV), and pharmaceuti... |
|
|
Invention
|
Oral complement factor d inhibitors. Disclosed are compounds of formula (I), and pharmaceuti- cal... |
|
|
Invention
|
Oral complement factor d inhibitors. Disclosed are compounds of formula (I), and pharmaceutically... |
|
|
Invention
|
Indole compounds and analogues thereof. Disclosed are compounds of formula I, and pharmaceuticall... |
|
|
Invention
|
Prodrugs of kallikrein inhibitors. Disclosed are compounds of formula I, II, and III, and pharmac... |
|
|
Invention
|
Process-scale synthesis of a plasma kallikrein inhibitor.
Disclosed are methods of preparing Com... |
|
|
Invention
|
Dosing regimens for oral complement factor d inhibitors.
Disclosed are compounds and pharmaceuti... |
|
|
Invention
|
Human plasma kallikrein inhibitors. Disclosed are compounds of formula I:
as described herei... |
|
|
Invention
|
Plasma kallikrein inhibitors and methods of use thereof in ocular disorders.
This disclosure is ... |
|
2019
|
P/S
|
Providing health and wellness information to patients and patients' families regarding disease aw... |
|
2018
|
P/S
|
Pharmaceutical preparations for the treatment of hereditary
angioedema. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of hereditary angioedema |
|
|
P/S
|
Pharmaceutical preparations for the treatment of hereditary angioedema. |
|
|
P/S
|
Pharmaceuticals for the treatment of infectious, viral, inflammatory, immunological, autoimmune a... |
|
|
P/S
|
Pharmaceuticals for the treatment of infectious, viral, inflammatory, and immunological diseases ... |
|
|
P/S
|
Pharmaceuticals for the treatment of infectious, viral
inflammatory, immunological, autoimmune a... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of hereditary angioedema |
|
|
P/S
|
Pharmaceutical research and drug development; medical and scientific research, namely, conducting... |
|
|
P/S
|
Pharmaceuticals for the treatment of hereditary angioedema |
|
2017
|
P/S
|
Pharmaceutical products, namely, preparations and substances for the treatment of cancers and imm... |
|
2016
|
P/S
|
Pharmaceutical antiviral preparations; vaccines. |
|
|
P/S
|
Antivirals; vaccine for human use |
|
|
P/S
|
Pharmaceutical preparations; Anti-viral agents; Vaccines. |
|
|
P/S
|
Pharmaceuticals for the treatment of autoimmune and cardiovascular diseases and disorders; pharma... |
|
2015
|
P/S
|
Pharmaceutical antiviral preparation. |
|
|
P/S
|
Pharmaceutical antiviral preparation |
|
|
P/S
|
pharmaceutical preparations; antivirals. |
|
2013
|
P/S
|
pharmaceutical antiviral preparation |
|
2007
|
P/S
|
Pharmaceutical products, namely, preparations and substances
for the treatment of cancers and im... |
|
2005
|
P/S
|
Pharmaceutical products, namely preparations and substances
for the treatment of cancers and imm... |
|
2002
|
P/S
|
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic ... |
|
|
P/S
|
Pharmaceuticals for the treatment of viral, inflammatory, autoimmune, cancer [ and cardiovascular... |
